Adriamycin

(Doxorubicin)

ApprovedSmall molecule

Doxorubicin is a chemotherapy drug used to treat various types of cancer by damaging cancer cells and stopping them from growing and dividing. It's commonly used for breast cancer, lymphomas, and leukemias.[2] Adriamycin is currently approved and in use across 107 indications[4].[1]

Adriamycin is one of 1169 small molecule programs targeting Acute Lymphoblastic Leukemia. It is currently in Approved.

107

Indications

691

Total Trials

Active Trials

1,168

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Acute Lymphoblastic LeukemiaCompleted

Classic Hodgkin LymphomaActive, not recruiting

Soft Tissue SarcomaCompleted

Diffuse Intrinsic Pontine GliomaRecruiting

Solid TumorsRecruiting

Triple-Negative Breast CancerUnknown status

LeiomyosarcomaRecruiting

Bladder CancerActive, not recruiting

LenalidomideRecruiting

Diffuse Large B-Cell LymphomaCompleted

Acute Lymphoblastic LeukemiaApproved

Completed

Classic Hodgkin LymphomaPhase 2

Active, not recruiting

Soft Tissue SarcomaPhase 3

Completed

Diffuse Intrinsic Pontine GliomaPhase 2

Recruiting

Solid TumorsPhase 1

Recruiting

Triple-Negative Breast CancerPhase 2

Unknown status

LeiomyosarcomaPhase 3

Recruiting

Bladder CancerPhase 3

Active, not recruiting

LenalidomidePhase 2

Recruiting

Diffuse Large B-Cell LymphomaPhase 3

Completed

Showing 10 of 106 indications

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adriamycin

Blenoxane

1 3

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 4

Duragesic

CCephalon

Preclinical

1 5

Vfend

PPrism Pharmaceuticals

Preclinical

—6

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 7

Ablavar

LLantheus Medical Imaging

Preclinical

2 8

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 9

Bisphosphonate

Amgen

Preclinical

2 10

Tc99m Sestamibi

MM.D. Anderson Cancer Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2/3Active, not recruiting

Soft Tissue Sarcoma

NCT02180867

Phase 3Recruiting

Ovarian Cancer

NCT06394492

Phase 2Recruiting

Lymphoma

NCT04922567

Phase 2Active, not recruiting

Advanced Sarcoma

NCT03719430

Q2 2027

Phase 2Active, not recruiting

Breast Cancer

NCT06531447

Recruiting

Real-World Study

NCT05899621

Clinical

Trials by Indication[1]

Breast Cancer44 trials

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer

Not yet recruiting·FFudan University·Phase 2·NCT06404463·76 enrolled

Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer

Completed·PPriyanka Sharma·Phase 2·NCT02413320·101 enrolled

LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer

Withdrawn·WWake Forest University Health Sciences·Phase 1·NCT04762901

Show 41 more trials

Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer

Terminated· Sanofi logo

Sanofi·Phase 2·NCT00461344·20 enrolled

Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed

Completed·NNSABP Foundation Inc·Phase 3·NCT00002707·2,411 enrolled

Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer

Completed·MMassachusetts General Hospital·Phase 2·NCT00580333·51 enrolled

Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen

Completed· Roche logo

Roche·Phase 4·NCT02419742·110 enrolled

A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer

Terminated·HHoosier Cancer Research Network··NCT00235235·80 enrolled

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT03101748·34 enrolled

Docetaxel in Node Positive Adjuvant Breast Cancer

Completed· Sanofi logo

Sanofi·Phase 3·NCT00688740·1,491 enrolled

Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer

Completed·—·Phase 2·NCT00146562·135 enrolled

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT03197935·333 enrolled

A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00102219·77 enrolled

Neoadjuvant Carboplatin in Triple Negative Breast Cancer

Completed·—·Phase 2·NCT02978495·154 enrolled

Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

Completed·—·Phase 2·NCT00546156·104 enrolled

First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

Active, not recruiting·TThe National Center of Oncology, Azerbaijan·Phase 2·NCT06531447·200 enrolled

A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT01998906·330 enrolled

TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen

Withdrawn·JJules Bordet Institute·Phase 2·NCT02053597

Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)

Completed· Amgen logo

Amgen·Phase 2·NCT00115414

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Recruiting·SSWOG Cancer Research Network·Phase 3·NCT05929768·2,400 enrolled

A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00001498·55 enrolled

Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193115·32 enrolled

Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.

Completed·SSOLTI Breast Cancer Research Group·Phase 2·NCT03248427·106 enrolled

Vaccination of Triple Negative Breast Cancer Patients

Completed·UUniversity of Arkansas·Phase 1/2·NCT02938442·16 enrolled

Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer

Completed·OOhio State University Comprehensive Cancer Center·Phase 2·NCT00201708·56 enrolled

Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients

Completed·SSpanish Breast Cancer Research Group·Phase 2·NCT00129376·63 enrolled

Fasting on Newly Diagnosed Breast Cancer

Terminated·WWestern Regional Medical Center·Phase 1/2·NCT02379585·8 enrolled

Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00336791·273 enrolled

A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT01964391·174 enrolled

Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00149214·257 enrolled

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Completed·RRoswell Park Cancer Institute·Phase 1·NCT04081389·9 enrolled

Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer

Completed·SSCRI Development Innovations, LLC·N/A·NCT00544167·45 enrolled

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT01358877·4,804 enrolled

A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT01940497·240 enrolled

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

Unknown status·NNSABP Foundation Inc·Phase 2·NCT03412643·64 enrolled

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Active, not recruiting·SSpanish Breast Cancer Research Group·Phase 2·NCT04293393·200 enrolled

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT04024462·200 enrolled

TAC Versus TC for Adjuvant Breast Cancer

Completed·UUS Oncology Research·Phase 3·NCT00493870·1,961 enrolled

Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer

Completed·RRita Sanghvi, Mehta·Phase 2·NCT00256243·48 enrolled

Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment

Completed·SSpanish Breast Cancer Research Group·Phase 3·NCT00121992·1,060 enrolled

Correlation Between Genetic Variants and Long-term Cardiac Effects Induced by Doxorubicin in Breast Cancer Patients

Unknown status·NNational University Hospital, Singapore··NCT02078388·500 enrolled

Molecular Triaging of Newly Diagnosed Breast Cancer

Withdrawn·MM.D. Anderson Cancer Center·N/A·NCT01159236

Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer

Active, not recruiting·UUniversity of Illinois at Chicago·Phase 2·NCT04083963·13 enrolled

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

Terminated· GSK logo

GSK·Phase 2·NCT01220128·66 enrolled

Lymphoma31 trials

BV-AVD-R Treatment Children Hodgkin's Lymphoma

Unknown status·—·Phase 2·NCT06201507·44 enrolled

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

Active, not recruiting· Takeda logo

Takeda·Phase 2·NCT05673785·52 enrolled

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00787527·14 enrolled

Show 28 more trials

CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study

Unknown status·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT01719835·87 enrolled

Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment

Unknown status·BBritish Columbia Cancer Agency·Phase 2·NCT00324467·150 enrolled

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

Unknown status·PPeking University·Phase 3·NCT03952572·244 enrolled

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

Terminated·—·Phase 2·NCT00126191·10 enrolled

Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00299182·50 enrolled

PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma

Terminated·UUniversity of Cologne·Phase 2·NCT00512980

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

Completed· Roche logo

Roche·Phase 1/2·NCT02055820·267 enrolled

CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma

Unknown status·RRuijin Hospital·Phase 4·NCT01746992·200 enrolled

Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma

Completed·MMeir Medical Center·Phase 4·NCT00969462·18 enrolled

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT02228512

PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00054665·50 enrolled

Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

Completed·UUniversity of Cologne·Phase 2·NCT01569204·100 enrolled

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00001337·348 enrolled

A Phase I/II Trial of VR-CHOP in Lymphoma Patients

Completed·EEmory University·Phase 1/2·NCT00634179·37 enrolled

Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin

Completed·TThe Lymphoma Academic Research Organisation·Phase 2·NCT02414568·90 enrolled

Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT04922567·289 enrolled

Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma

Completed·WWeill Medical College of Cornell University·Phase 1/2·NCT01004991·14 enrolled

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

Completed· Roche logo

Roche·Phase 3·NCT01332968·1,401 enrolled

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00577993·210 enrolled

Prospective Study on HIV-related Hodgkin Lymphoma

Unknown status·HHarlachinger Krebshilfe e.V.·Phase 2·NCT01468740·130 enrolled

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Terminated· Pfizer logo

Pfizer·Phase 2·NCT03646123·255 enrolled

Treatment of Disseminated High Grade Lymphoma

Completed·FFrench Innovative Leukemia Organisation·Phase 2/3·NCT00536393·100 enrolled

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT01415765

A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT02529852·59 enrolled

Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.

Completed·TThe Lymphoma Academic Research Organisation·Phase 2·NCT02292979·170 enrolled

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT03755804·232 enrolled

BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma

Recruiting·UUniversity of Miami·Phase 2·NCT07002216·48 enrolled

A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT00825149·137 enrolled

Diffuse Large B-Cell Lymphoma13 trials

A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Active, not recruiting·PPatrick Reagan·Phase 2·NCT02734771·24 enrolled

ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Terminated·DDeepa Jagadeesh·Phase 1/2·NCT04517435·13 enrolled

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Terminated· Pfizer logo

Pfizer·Phase 2·NCT02855359·24 enrolled

Show 10 more trials

The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma

Unknown status·WWuhan University·Phase 3·NCT02449278·120 enrolled

Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma

Unknown status·RRuijin Hospital·Phase 1/2·NCT02951728·58 enrolled

A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma

Recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 1/2·NCT07124936·97 enrolled

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Terminated· Roche logo

Roche·Phase 1·NCT04790903·50 enrolled

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

Active, not recruiting· Roche logo

Roche·Phase 3·NCT03274492·1,000 enrolled

Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma

Completed·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 2·NCT00575406·94 enrolled

ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1

Completed·LLymphoma Study Association·Phase 3·NCT00140595·380 enrolled

ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma

Completed·LLymphoma Study Association·Phase 2·NCT00144807·128 enrolled

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Roche logo

Roche·Phase 1/2·NCT02596971·91 enrolled

R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma

Terminated·LLymphoma Study Association·Phase 3·NCT00135499·138 enrolled

Acute Lymphoblastic Leukemia10 trials

Treatment of Older Adults With Acute Lymphoblastic Leukemia

Completed·MMassachusetts General Hospital·Phase 2·NCT00973752·30 enrolled

Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

Terminated·EEhab L Atallah·Phase 1·NCT01887587·5 enrolled

Treatment of Acute Lymphoblastic Leukemia in Children

Completed·—·Phase 3·NCT00165178·498 enrolled

Show 7 more trials

Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00890656·90 enrolled

Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study

Unknown status·NNational University Hospital, Singapore·Phase 4·NCT02894645·500 enrolled

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02420717·11 enrolled

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

Recruiting·MMartin Schrappe·Phase 3·NCT03643276·5,000 enrolled

Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia

Terminated·SSt. Jude Children's Research Hospital·Phase 1·NCT03515200·12 enrolled

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Completed·UUniversity of Washington·Phase 2·NCT03023046·54 enrolled

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

Completed·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT00440726·31 enrolled

Soft Tissue Sarcoma9 trials

A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT03283696·24 enrolled

Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)

Unknown status·PPhilogen S.p.A.·Phase 2·NCT03420014·114 enrolled

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2/3·NCT02180867·140 enrolled

Show 6 more trials

Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma

Completed· Amgen logo

Amgen·Phase 1/2·NCT00626704·134 enrolled

Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma

Active, not recruiting·FFox Chase Cancer Center··NCT04055753·24 enrolled

Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

Completed·IImmunityBio, Inc.·Phase 2·NCT01514188·126 enrolled

A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00001300·150 enrolled

A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT04780464·14 enrolled

Post-Operative Chemoradiation for Extremity & Trunk Soft Tissue Sarcoma

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00502411·4 enrolled

60 more indications

Doxorubicin7 trials

Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS

Terminated·GGrupo Espanol de Investigacion en Sarcomas·Phase 2·NCT01104298·115 enrolled

Chemoembolization Using LifePearl Polyethylene Glycol Drug Eluting Microspheres With Doxorubicin in HCC

Unknown status·IInternational Group of Endovascular Oncology··NCT03734068·100 enrolled

Dose Finding Study of L19TNF and Doxorubicin in Patients With STS

Active, not recruiting·PPhilogen S.p.A.·Phase 1·NCT04032964·2 enrolled

Show 4 more trials

Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG

Recruiting·IInSightec·Phase 1/2·NCT05615623·10 enrolled

Phase II Study of Doxorubicin and Avastin® in Sarcoma.

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00755261·4 enrolled

Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers

Completed·VVirginia Commonwealth University·Phase 1·NCT01375699·26 enrolled

PCI-24781 in Combination With Doxorubicin to Treat Sarcoma

Completed·MMassachusetts General Hospital·Phase 1/2·NCT01027910·20 enrolled

Follicular Lymphoma6 trials

Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06704555·20 enrolled

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT06911502·400 enrolled

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Withdrawn·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 3·NCT06313996

Show 3 more trials

Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma

Completed· Takeda logo

Takeda·Phase 2·NCT00715208·55 enrolled

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

Active, not recruiting· Gilead logo

Gilead·Phase 3·NCT05371093·231 enrolled

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Recruiting·UUniversity of Birmingham·Phase 2·NCT05848765·284 enrolled

Hepatocellular Carcinoma5 trials

Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma

Withdrawn·AAlbert Koong·Phase 3·NCT01327521

Pharmacogenetic Study in Hepatocellular Carcinoma Patients.

Completed·RRehab Werida··NCT05291338·107 enrolled

Comparison of TACE Versus TACE/TACI Combination in Advanced Hepatocellular Carcinoma With Portal Vein Invasion

Withdrawn·SSeoul National University Hospital·N/A·NCT01857726

Show 2 more trials

Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients

Completed· Sanofi logo

Sanofi·Phase 3·NCT00471965·371 enrolled

Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma

Completed·VValerio Therapeutics·Phase 3·NCT01655693·397 enrolled

Mantle Cell Lymphoma4 trials

Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00477412·107 enrolled

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Completed· Teva logo

Teva·Phase 3·NCT00877006·447 enrolled

S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00041132·56 enrolled

Show 1 more trial

EDOCH Alternating With DHAP for New Diagnosed Younger MCL

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 4·NCT02858804·55 enrolled

Ovarian Cancer3 trials

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT06394492·440 enrolled

JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer

Not yet recruiting·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 3·NCT06751485·430 enrolled

HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Recruiting·HHansoh BioMedical R&D Company·Phase 3·NCT06855069·468 enrolled

Prostate Cancer3 trials

Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer

Terminated·UUniversity of Kentucky·Phase 2·NCT00176293·2 enrolled

Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer

Terminated·TThe University of Texas Health Science Center, Houston·Phase 2·NCT02494713·4 enrolled

Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer

Terminated·TThe University of Texas Health Science Center, Houston·Phase 2·NCT02560051·19 enrolled

Bladder Cancer3 trials

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

Completed·UUniversity of Washington·Phase 2·NCT04383743·17 enrolled

S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT02177695·237 enrolled

Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer

Terminated·HHellenic Oncology Research Group·Phase 2·NCT00635726·41 enrolled

Advanced Sarcoma2 trials

GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma

Recruiting·SSarcoma Oncology Research Center, LLC·Phase 2·NCT04535713·260 enrolled

APX005M and Doxorubicin in Advanced Sarcoma

Active, not recruiting·—·Phase 2·NCT03719430·27 enrolled

Multiple Myeloma2 trials

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

Completed·UUniversity of Arkansas·Phase 3·NCT00083551·668 enrolled

CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma

Unknown status·SSun Yat-sen University·Phase 3·NCT02362165·236 enrolled

Adult Acute Lymphoblastic Leukemia2 trials

High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)

Unknown status·JJapan Adult Leukemia Study Group·Phase 3·NCT00131027·240 enrolled

Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia

Completed·RRuijin Hospital·Phase 4·NCT01358253·100 enrolled

Leukemia2 trials

EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma

Completed·WWashington University School of Medicine·Phase 1/2·NCT01000285·18 enrolled

Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00038610·54 enrolled

Neoadjuvant Chemotherapy2 trials

Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy

Unknown status·JJilin University·Phase 2·NCT02953184·160 enrolled

Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00506155·60 enrolled

Pancreatic Cancer2 trials

L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer

Terminated·HHelix BioPharma Corporation·Phase 1/2·NCT04203641·28 enrolled

Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients

Unknown status·MMoscow Clinical Scientific Center··NCT05580887·35 enrolled

Rhabdomyosarcoma2 trials

Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT03111069

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

Recruiting·UUniversity of Birmingham·Phase 1/2·NCT04625907·1,672 enrolled

Osteosarcoma2 trials

A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT00667342·43 enrolled

A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response

Terminated·UUniversity of Chicago·Phase 1·NCT01258634·2 enrolled

Endometrial Cancer2 trials

Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer

Completed·AAEterna Zentaris·Phase 3·NCT01767155·511 enrolled

A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer

Terminated·RR-Pharm·Phase 3·NCT00883116·551 enrolled

Brentuximab Vedotin1 trial

Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment

Recruiting·CChildren's Cancer Group, China·Phase 2/3·NCT06563245·96 enrolled

Cervical Cancer1 trial

Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer

Active, not recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 2·NCT03340376·48 enrolled

Cytoreductive Surgery1 trial

Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers

Completed·HHoly Name Medical Center, Inc.··NCT03604653·10 enrolled

Leiomyosarcoma1 trial

Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT02997358·150 enrolled

Adrenocortical Carcinoma1 trial

Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)

Completed·CCollaborative Group for Adrenocortical Carcinoma Treatment·Phase 3·NCT00094497·304 enrolled

Renal Cell Carcinoma1 trial

Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00068393·39 enrolled

Solid Tumors1 trial

Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors

Completed·AAGC Biologics S.p.A.·Phase 1·NCT00305084·15 enrolled

Advanced Solid Tumours1 trial

L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours

Completed·PPhilogen S.p.A.·Phase 1·NCT02076620·29 enrolled

Real-world Study1 trial

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting·RRuijin Hospital··NCT05899621·332 enrolled

Monotherapy1 trial

Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient

Unknown status·SShi-Ming Lin·Phase 2·NCT01858207·60 enrolled

Childhood Acute Lymphoblastic Leukemia1 trial

Treatment of Childhood Acute Lymphoblastic Leukemia

Terminated·—·Phase 3·NCT00165087·491 enrolled

Efficacy and Safety1 trial

An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00796120·121 enrolled

Diffuse Intrinsic Pontine Glioma1 trial

Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)

Recruiting·IInSightec·Phase 1/2·NCT05630209·10 enrolled

Radiation Therapy1 trial

Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma

Withdrawn· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00017160

Cardiotoxicity1 trial

Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients

Completed·TTanta University·Phase 2·NCT06155331·44 enrolled

Advanced Stage1 trial

Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL

Completed·—·Phase 1/2·NCT00379574·49 enrolled

Pediatric Brain Tumor1 trial

Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors

Terminated·WWashington University School of Medicine·Phase 2·NCT02372409·6 enrolled

Metastatic Sarcoma1 trial

YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

Unknown status·TTracon Pharmaceuticals Inc.·Phase 1/2·NCT05448820·15 enrolled

T-cell acute lymphoblastic leukemia1 trial

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT06210750

Sorafenib1 trial

Study in Asia of the Combination of TACE With Sorafenib in HCC Patients

Unknown status·TTaipei Veterans General Hospital, Taiwan·Phase 2·NCT00990860·36 enrolled

Malignancies1 trial

Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies

Withdrawn·—·Phase 4·NCT02853500

Clear Cell Carcinoma1 trial

Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium

Unknown status·NNHS Greater Glasgow and Clyde·Phase 2·NCT02866370·120 enrolled

Induction Chemotherapy1 trial

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

Unknown status·EEuropean Mantle Cell Lymphoma Network·Phase 3·NCT00209209·570 enrolled

Hypofractionated Radiotherapy1 trial

Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment

Unknown status·—·Phase 2·NCT02812654·70 enrolled

Combination Therapy1 trial

Combination Therapy of Anthracyclines for Children With Nephroblastoma

Not yet recruiting·SShengjing Hospital·Phase 4·NCT03892330·120 enrolled

Pediatric Patients1 trial

Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients

Terminated·MMayo Clinic·Phase 1·NCT04213794·2 enrolled

Triple-Negative Breast Cancer1 trial

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Completed· Roche logo

Roche·Phase 1·NCT04584112·83 enrolled

Treatment1 trial

Genotype-guided Treatment in DLBCL

Recruiting·RRuijin Hospital·Phase 3·NCT05351346·1,100 enrolled

Cholangiocarcinoma1 trial

International Registry on Cholangiocarcinoma Treatment

Unknown status·IInternational Group of Endovascular Oncology··NCT01920503·40 enrolled

Endometrial Carcinoma1 trial

Lenvatinib in Second Line Endometrial Carcinoma

Withdrawn·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT03005015

Resectable Sarcoma1 trial

A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas

Completed·MMassachusetts General Hospital·Phase 2·NCT02448537·42 enrolled

Propranolol1 trial

Use of Propranolol Hydrochloride in the Treatment of Metastatic STS

Unknown status·—·Phase 2·NCT03108300·50 enrolled

Adenocarcinoma1 trial

Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus

Completed·—·Phase 2·NCT00165191·32 enrolled

Lymphoblastic Lymphoma1 trial

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

Recruiting·UUniversity Hospital Muenster·Phase 3·NCT04043494·683 enrolled

Efficacy1 trial

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Not yet recruiting·RRuijin Hospital·Phase 2·NCT06441097·152 enrolled

Necrosis1 trial

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

Completed·MMara Chambers·Phase 2·NCT01205503·32 enrolled

Chemotherapy1 trial

Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)

Terminated·UUniversity of Miami·Phase 2·NCT00450385·57 enrolled

EBV-Positive DLBCL, Nos1 trial

Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04181489·55 enrolled

Metastases1 trial

In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma

Recruiting·UUniversity Health Network, Toronto·Phase 1·NCT02811523·17 enrolled

CHOP1 trial

Ph II CHOP+Velcade in Mediastinal LBCL

Terminated·—·Phase 2·NCT00361621·3 enrolled

B-cell Malignancies1 trial

Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies

Completed·—·Phase 1·NCT01760226·4 enrolled

Stem Cell Transplant1 trial

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00051311·62 enrolled

Elderly Patients1 trial

Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients

Terminated·IIstituto Oncologico Veneto IRCCS·Phase 3·NCT04656262·79 enrolled

Neuroblastoma1 trial

Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT00808899·4 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

DOXORUBICIN HYDROCHLORIDE

NDA NDA050467

Dec 23, 1987

DOXORUBICIN HYDROCHLORIDE

NDA NDA050629

Nov 17, 1995

DOXIL (LIPOSOMAL)

NDA NDA050718

Sources

References

[1]
ClinicalTrials.gov — 691 trial records for Doxorubicin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Adriamycin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Doxorubicin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Doxorubicin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA050718). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: DNA Topoisomerase II Alpha Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Pfizer

Adriamycin

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Breast Cancer44 trials

Lymphoma31 trials

Diffuse Large B-Cell Lymphoma13 trials

Acute Lymphoblastic Leukemia10 trials

Soft Tissue Sarcoma9 trials

Doxorubicin7 trials

Follicular Lymphoma6 trials

Hepatocellular Carcinoma5 trials

Mantle Cell Lymphoma4 trials

Ovarian Cancer3 trials

Prostate Cancer3 trials

Bladder Cancer3 trials

Advanced Sarcoma2 trials

Multiple Myeloma2 trials

Adult Acute Lymphoblastic Leukemia2 trials

Leukemia2 trials

Neoadjuvant Chemotherapy2 trials

Pancreatic Cancer2 trials

Rhabdomyosarcoma2 trials

Osteosarcoma2 trials

Endometrial Cancer2 trials

Brentuximab Vedotin1 trial

Cervical Cancer1 trial

Cytoreductive Surgery1 trial

Leiomyosarcoma1 trial

Adrenocortical Carcinoma1 trial

Renal Cell Carcinoma1 trial

Solid Tumors1 trial

Advanced Solid Tumours1 trial

Real-world Study1 trial

Monotherapy1 trial

Childhood Acute Lymphoblastic Leukemia1 trial

Efficacy and Safety1 trial

Diffuse Intrinsic Pontine Glioma1 trial

Radiation Therapy1 trial

Cardiotoxicity1 trial

Advanced Stage1 trial

Pediatric Brain Tumor1 trial

Metastatic Sarcoma1 trial

T-cell acute lymphoblastic leukemia1 trial

Sorafenib1 trial

Malignancies1 trial

Clear Cell Carcinoma1 trial

Induction Chemotherapy1 trial

Hypofractionated Radiotherapy1 trial

Combination Therapy1 trial

Pediatric Patients1 trial

Triple-Negative Breast Cancer1 trial

Treatment1 trial

Cholangiocarcinoma1 trial

Endometrial Carcinoma1 trial

Resectable Sarcoma1 trial

Propranolol1 trial

Adenocarcinoma1 trial

Lymphoblastic Lymphoma1 trial

Efficacy1 trial

Necrosis1 trial

Chemotherapy1 trial

EBV-Positive DLBCL, Nos1 trial

Metastases1 trial

CHOP1 trial

B-cell Malignancies1 trial

Stem Cell Transplant1 trial

Elderly Patients1 trial

Neuroblastoma1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News